Nationally Ranked Investors Rights Firm Holzer and Holzer LLC Announces Investigation of KalVista (KALV)
KalVista Pharmaceuticals (NASDAQ: KALV) is under investigation by Holzer & Holzer, LLC for potential violations of federal securities laws.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
KalVista Pharmaceuticals (NASDAQ: KALV) is under investigation by Holzer & Holzer, LLC for potential violations of federal securities laws. This follows the termination of its KOMPLETE phase 2 clinical trial for KVD824 on October 4, 2022, due to elevated liver enzymes observed in all treatment groups. This announcement resulted in a drop in the company's stock price. Investors who incurred losses on their KalVista stock are encouraged to contact Holzer & Holzer for legal advice regarding their rights.
Positive
- None.
Negative
- Termination of KOMPLETE phase 2 clinical trial for KVD824 due to liver enzyme elevations.
- Drop in stock price following the announcement of trial termination.
Details
News Market Reaction – KALV
The recorded move for KALV in the trading session of this news was +0.41%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ATLANTA, GA / ACCESSWIRE / October 6, 2022 / Holzer & Holzer, LLC is investigating whether KalVista Pharmaceuticals, Inc. ("KalVista" or the "Company") (NASDAQ:KALV) complied with federal securities laws. On October 4, 2022, the Company announced it had terminated its KOMPLETE phase 2 clinical trial for KVD824 due to the observation of liver enzyme elevations in all trial treatment groups. After this announcement, the Company's stock price dropped.
If you purchased KalVista stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/kalvista to discuss your legal rights.
Holzer & Holzer, LLC, a Top 50 securities litigation law firm for 2021, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct.More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.
CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
cholzer@holzerlaw.com
SOURCE: Holzer & Holzer
View source version on accesswire.com:
https://www.accesswire.com/719414/Nationally-Ranked-Investors-Rights-Firm-Holzer-and-Holzer-LLC-Announces-Investigation-of-KalVista-KALV
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.